Biomarker Tests Benefit Certain Cancer Patients
By LabMedica International staff writers Posted on 17 Sep 2018 |
Image: The Oncotype DX analyzes 21 genes in the tumor to estimate a woman\'s risk of the cancer coming back after surgery (Photo courtesy of Genomic Health).
The benefit of biomarker tests has been reinvestigated to support the decision for or against adjuvant systemic chemotherapy in certain breast cancer patients, that is, women with primary hormone receptor-positive, HER2/neu-negative breast cancer and 0 to 3 affected lymph nodes.
The available biomarker tests aim to assess whether a woman would develop recurrences if she omitted chemotherapy in addition to hormonal therapy, i.e. if her breast cancer would return. Each test analyses the expression of a different group of genes. It is therefore possible that some tests are better at predicting the risk of recurrence than a clinician, who looks at factors such as tumor size and type of tumor tissue, whereas other tests are not.
Scientists at the German Institute for Quality and Efficiency in Health Care (IQWIG, Köln, Germany) investigated the TAILORx study which questioned whether, in women with intermediate Oncotype (Genomic Health, Redwood City, CA, USA) risk score (11 to 25), recurrences were notably more frequent without additional chemotherapy than with chemotherapy.
For all participants overall, there were no statistically significant differences. The women’s age apparently made a difference, however: For patients over 50 years of age or after menopause, the number of recurrences was about the same with and without chemotherapy; hence this group benefited from a test-based decision against chemotherapy. In participants under 50 years of age or before menopause, in contrast, chemotherapy had significant advantages.
Women with risk scores below 11 and above 25 were not randomized in the study. Instead, participants with low scores were not to receive chemotherapy, whereas participants with high-risk scores were to receive this kind of treatment. However, plausible assumptions can be made on the basis of further study data and analyses of subgroups with the values of 11 to 15, 16 to 20, and 21 to 25. According to these assumptions, older women with risk scores between 0 and 25, and younger women with risk scores between 0 and 10 without affected lymph nodes can omit chemotherapy without notably increasing their risk of recurrence. Naturally, women for whom the decision for or against chemotherapy is already clear based on other factors are exempt from this recommendation.
Stefan Lange, MD, PhD, deputy director of the IQWIG, said, “A comparison with the other studies reveals two things. First, the disease event rates of about 15% to 17% were substantially higher than in the MINDACT study, for example. This means that notably more women had recurrences. In principle, this could be expected as the observation period of up to nine years was longer than in the study data available so far. We had noted in the final report that it is rather common for breast cancer to return only after many years, which is why five-year data are unsuitable for reliable conclusions. However, it is still remarkable that chemotherapy did not reduce the risk of recurrence at all in older study participants.”
Related Links:
German Institute for Quality and Efficiency in Health Care
Oncotype
The available biomarker tests aim to assess whether a woman would develop recurrences if she omitted chemotherapy in addition to hormonal therapy, i.e. if her breast cancer would return. Each test analyses the expression of a different group of genes. It is therefore possible that some tests are better at predicting the risk of recurrence than a clinician, who looks at factors such as tumor size and type of tumor tissue, whereas other tests are not.
Scientists at the German Institute for Quality and Efficiency in Health Care (IQWIG, Köln, Germany) investigated the TAILORx study which questioned whether, in women with intermediate Oncotype (Genomic Health, Redwood City, CA, USA) risk score (11 to 25), recurrences were notably more frequent without additional chemotherapy than with chemotherapy.
For all participants overall, there were no statistically significant differences. The women’s age apparently made a difference, however: For patients over 50 years of age or after menopause, the number of recurrences was about the same with and without chemotherapy; hence this group benefited from a test-based decision against chemotherapy. In participants under 50 years of age or before menopause, in contrast, chemotherapy had significant advantages.
Women with risk scores below 11 and above 25 were not randomized in the study. Instead, participants with low scores were not to receive chemotherapy, whereas participants with high-risk scores were to receive this kind of treatment. However, plausible assumptions can be made on the basis of further study data and analyses of subgroups with the values of 11 to 15, 16 to 20, and 21 to 25. According to these assumptions, older women with risk scores between 0 and 25, and younger women with risk scores between 0 and 10 without affected lymph nodes can omit chemotherapy without notably increasing their risk of recurrence. Naturally, women for whom the decision for or against chemotherapy is already clear based on other factors are exempt from this recommendation.
Stefan Lange, MD, PhD, deputy director of the IQWIG, said, “A comparison with the other studies reveals two things. First, the disease event rates of about 15% to 17% were substantially higher than in the MINDACT study, for example. This means that notably more women had recurrences. In principle, this could be expected as the observation period of up to nine years was longer than in the study data available so far. We had noted in the final report that it is rather common for breast cancer to return only after many years, which is why five-year data are unsuitable for reliable conclusions. However, it is still remarkable that chemotherapy did not reduce the risk of recurrence at all in older study participants.”
Related Links:
German Institute for Quality and Efficiency in Health Care
Oncotype
Latest Pathology News
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy